VRPX vs. ABVC, KZIA, ONVO, ELAB, VRAX, LIXT, IMCC, ONCO, PRTG, and ADIL
Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include ABVC BioPharma (ABVC), Kazia Therapeutics (KZIA), Organovo (ONVO), Elevai Labs (ELAB), Virax Biolabs Group (VRAX), Lixte Biotechnology (LIXT), IM Cannabis (IMCC), Onconetix (ONCO), Portage Biotech (PRTG), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry.
Virpax Pharmaceuticals vs.
ABVC BioPharma (NASDAQ:ABVC) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.
Virpax Pharmaceuticals has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. ABVC BioPharma's return on equity of -104.94% beat Virpax Pharmaceuticals' return on equity.
Virpax Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 1,042.42%. Given Virpax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Virpax Pharmaceuticals is more favorable than ABVC BioPharma.
11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 11.9% of ABVC BioPharma shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
ABVC BioPharma has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
ABVC BioPharma has higher revenue and earnings than Virpax Pharmaceuticals.
Virpax Pharmaceuticals received 3 more outperform votes than ABVC BioPharma when rated by MarketBeat users.
In the previous week, ABVC BioPharma had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for Virpax Pharmaceuticals. ABVC BioPharma's average media sentiment score of 0.55 beat Virpax Pharmaceuticals' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media.
Summary
ABVC BioPharma beats Virpax Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Virpax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virpax Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRPX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free VRPX Stock Alerts